Genzyme to sell genetic testing business for $925 million
This article was originally published in Scrip
Executive Summary
In an apparent show of its management's ability to improve its precarious financial situation, Genzyme is to divest its genetic testing division Genzyme Genetics for $925 million in cash to Laboratory Corporation of America (LabCorp).